Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CNT037
MIFTS: 35

Central Nervous System Germinoma

Categories: Cancer diseases, Endocrine diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Central Nervous System Germinoma

About this section

MalaCards integrated aliases for Central Nervous System Germinoma:

Name: Central Nervous System Germinoma 12 54 15 74
Germinoma of the Central Nervous System 54 60
Intracranial Germinoma 54 74
Germinoma of Cns 12

Characteristics:

Orphanet epidemiological data:

60
germinoma of the central nervous system
Inheritance: Not applicable; Age of onset: Adolescent,Adult,Childhood;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases Endocrine diseases
See all MalaCards categories (disease lists)
Orphanet: 60  
Rare neurological diseases
Rare endocrine diseases


External Ids:

Disease Ontology 12 DOID:4438
NCIt 51 C7009
UMLS via Orphanet 75 C1333813
Orphanet 60 ORPHA91352
Sources

Summaries for Central Nervous System Germinoma

About this section
MalaCards based summary : Central Nervous System Germinoma, also known as germinoma of the central nervous system, is related to brain germinoma and diabetes insipidus. An important gene associated with Central Nervous System Germinoma is JMJD1C (Jumonji Domain Containing 1C), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and G alpha (s) signalling events. The drugs Carboplatin and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and liver.

Sources

Related Diseases for Central Nervous System Germinoma

About this section

Diseases in the Central Nervous System Germinoma family:

Adult Central Nervous System Germinoma

Diseases related to Central Nervous System Germinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 48)
# Related Disease Score Top Affiliating Genes
1 brain germinoma 32.6 AVP POU5F1
2 diabetes insipidus 30.1 AVP POMC
3 seminoma 29.9 ALPP POU5F1
4 childhood central nervous system germinoma 12.5
5 adult central nervous system germinoma 12.5
6 germinoma 10.6
7 malignant leydig cell tumor 10.1 POMC POU5F1
8 multiple sclerosis 10.1
9 embryonal carcinoma 10.1
10 medulloblastoma 10.0
11 lennox-gastaut syndrome 9.9 ALPP POMC
12 germ cell cancer 9.9 ALPP POU5F1
13 epidermoid cysts 9.9
14 smith-lemli-opitz syndrome 9.9
15 opitz gbbb syndrome, type i 9.9
16 hypogonadotropic hypogonadism 9.9
17 cauda equina syndrome 9.9
18 cornelia de lange syndrome 9.9
19 glioblastoma multiforme 9.9
20 teratoma 9.9
21 choriocarcinoma 9.9
22 polyradiculopathy 9.9
23 embryonal testis carcinoma 9.9
24 in situ carcinoma 9.9
25 hypopituitarism 9.9
26 glioblastoma 9.9
27 lymphocytic hypophysitis 9.9
28 tremor 9.9
29 growing teratoma syndrome 9.9
30 malignant teratoma 9.9 AVP POU5F1
31 tuberculous epididymitis 9.9 AVP POMC
32 lung oat cell carcinoma 9.9 AVP POMC
33 bronchus cancer 9.9 AVP POMC
34 inappropriate adh syndrome 9.9 AVP POMC
35 olfactory nerve neoplasm 9.9 AVP POMC
36 secondary hypertrophic osteoarthropathy 9.9 AVP POMC
37 syndrome of inappropriate antidiuretic hormone 9.8 AVP POMC
38 cervix small cell carcinoma 9.8 AVP POMC
39 diabetes insipidus, neurohypophyseal 9.8 AVP POMC
40 cranial nerve malignant neoplasm 9.8 AVP POMC
41 premenstrual tension 9.8 AVP POMC
42 chromophobe adenoma 9.8 AVP POMC
43 pituitary hormone deficiency, combined, 2 9.8 AVP POMC
44 pituitary gland disease 9.8 AVP POMC
45 pancreas disease 9.7 AVP POMC
46 central nervous system germ cell tumor 9.6 AVP POMC POU5F1
47 urinary system disease 9.6 AVP POMC
48 small cell cancer of the lung 9.5 AVP POMC

Graphical network of the top 20 diseases related to Central Nervous System Germinoma:



Diseases related to Central Nervous System Germinoma
Sources

Symptoms & Phenotypes for Central Nervous System Germinoma

About this section
Sources

Drugs & Therapeutics for Central Nervous System Germinoma

About this section

Drugs for Central Nervous System Germinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 38904 10339178 498142
2
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
3
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
4
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
5
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 441203 84093 2767
6
Sargramostim Approved, Investigational Phase 3,Phase 1 123774-72-1, 83869-56-1
7
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
8
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 1 1177-87-3
9
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
10
Ondansetron Approved Phase 3 99614-02-5 4595
11 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
12 Etoposide phosphate Phase 3,Phase 2,Phase 1
13 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
14 Immunologic Factors Phase 3,Phase 2,Phase 1
15 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
16 Alkylating Agents Phase 3,Phase 2,Phase 1
17 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
18 Antirheumatic Agents Phase 3,Phase 2,Phase 1
19 Adjuvants, Immunologic Phase 3,Phase 1
20 Gastrointestinal Agents Phase 3,Phase 1
21 Antiemetics Phase 3,Phase 1
22 Autonomic Agents Phase 3,Phase 1
23 BB 1101 Phase 3,Phase 1
24 Peripheral Nervous System Agents Phase 3,Phase 1
25 Emetics Phase 3
26
Bleomycin Approved, Investigational Phase 2 11056-06-7 5360373
27
Thiotepa Approved, Investigational Phase 2,Phase 1 52-24-4 5453
28
Mechlorethamine Approved, Investigational Phase 2,Phase 1 51-75-2 4033
29
Ifosfamide Approved Phase 2,Phase 1 3778-73-2 3690
30
Dasatinib Approved, Investigational Phase 1, Phase 2 302962-49-8 3062316
31 Anti-Bacterial Agents Phase 2,Phase 1
32 Antibiotics, Antitubercular Phase 2
33
Isophosphamide mustard Phase 2,Phase 1 0
34 Antimitotic Agents Phase 2,Phase 1
35 Protein Kinase Inhibitors Phase 1, Phase 2
36 Dermatologic Agents Phase 2
37 Podophyllotoxin Phase 2 518-28-5
38 Keratolytic Agents Phase 2
39 Liver Extracts Phase 1, Phase 2
40
Temozolomide Approved, Investigational Phase 1 85622-93-1 5394
41
Vorinostat Approved, Investigational Phase 1 149647-78-9 5311
42
Bortezomib Approved, Investigational Phase 1 179324-69-7 387447 93860
43
Levoleucovorin Approved, Investigational Phase 1 68538-85-2
44
leucovorin Approved Phase 1 58-05-9 6006 143
45
Fluorouracil Approved Phase 1 51-21-8 3385
46
Oxaliplatin Approved, Investigational Phase 1 61825-94-3 6857599 5310940 9887054 43805
47
Sunitinib Approved, Investigational Phase 1 557795-19-4, 341031-54-7 5329102
48
Nicotinamide Approved, Investigational Phase 1 98-92-0 936
49
Vincristine Approved, Investigational Phase 1 2068-78-2, 57-22-7 5978
50
Acetylcysteine Approved, Investigational Phase 1 616-91-1 12035

Interventional clinical trials:

(show all 19)
# Name Status NCT ID Phase Drugs
1 Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor Completed NCT00085098 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide
2 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
3 Chemotherapy Plus Reduced Radiotherapy in Intracranial Germinoma Unknown status NCT02782754 Phase 2 Carboplatin;Etoposide;Cyclophosphamide;Bleomycin
4 Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors Completed NCT00047320 Phase 2 carboplatin;etoposide;ifosfamide;thiotepa
5 Cisplatin and Etoposide Prior to Radiation Therapy in Treating Patients With CNS Tumors Completed NCT00002472 Phase 2 cisplatin;etoposide
6 Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors Active, not recruiting NCT01602666 Phase 2 Carboplatin;Etoposide;Ifosfamide
7 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
8 Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
9 Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma Completed NCT00994500 Phase 1 vorinostat;bortezomib
10 Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment Completed NCT00929903 Phase 1 pazopanib hydrochloride
11 Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors Completed NCT00281944 Phase 1 oxaliplatin;fluorouracil;leucovorin calcium
12 Sunitinib in Treating Young Patients With Refractory Solid Tumors Completed NCT00387920 Phase 1 sunitinib malate
13 Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma Completed NCT01273090 Phase 1 imetelstat sodium
14 PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors Completed NCT01158300 Phase 1 VEGF inhibitor PTC299
15 Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors Completed NCT00003141 Phase 1 carboplatin;cisplatin;cyclophosphamide;etoposide;thiotepa;vincristine sulfate
16 Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
17 Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors Terminated NCT00238173 Phase 1 acetylcysteine;carboplatin;cyclophosphamide;etoposide phosphate;mannitol;sodium thiosulfate
18 Collecting and Storing Tissue From Young Patients With Cancer Completed NCT00898755
19 Studying Cerebrospinal Fluid Proteins and Angiogenesis Proteins in Young Patients With Newly Diagnosed Central Nervous System Tumors Withdrawn NCT00897858

Search NIH Clinical Center for Central Nervous System Germinoma

Sources

Genetic Tests for Central Nervous System Germinoma

About this section
Sources

Anatomical Context for Central Nervous System Germinoma

About this section

MalaCards organs/tissues related to Central Nervous System Germinoma:

42
Brain, Spinal Cord, Liver, Bone, T Cells
Sources

Publications for Central Nervous System Germinoma

About this section

Articles related to Central Nervous System Germinoma:

(show all 16)
# Title Authors Year
1
Outcomes of children with central nervous system germinoma treated with multi-agent chemotherapy followed by reduced radiation. ( 26744133 )
2016
2
Improvement of Long-term Results with Neoadjuvant Chemotherapy andA Radiotherapy for Central Nervous System Germinoma. ( 26115804 )
2015
3
Feasibility of dasatinib in children and adolescents with new or recurrent central nervous system germinoma. ( 23754592 )
2013
4
An unusual case of primary central nervous system germinoma with meningeal dissemination. ( 22936081 )
2012
5
Neurocognitive outcomes in pediatric and adolescent patients with central nervous system germinoma treated with a strategy of chemotherapy followed by reduced-dose and volume irradiation. ( 21495164 )
2011
6
Outcome of central nervous system germinoma treatment by chemoradiation. ( 21516012 )
2011
7
Long-term follow-up of dose-adapted and reduced-field radiotherapy with or without chemotherapy for central nervous system germinoma. ( 20045266 )
2010
8
Regression of primary central nervous system germinoma after dexamethasone administration: a case report. ( 20367268 )
2010
9
Management of central nervous system germinoma: proposal for a modern strategy. ( 19329866 )
2009
10
Diffusion-weighted imaging characteristics of primary central nervous system germinoma with histopathologic correlation: a retrospective study. ( 19643635 )
2009
11
Outcome of patients with recurrent medulloblastoma or central nervous system germinoma treated with low dose continuous intravenous etoposide along with dose-intensive chemotherapy followed by autologous hematopoietic stem cell rescue. ( 19326417 )
2009
12
OCT4 immunohistochemistry is superior to placental alkaline phosphatase (PLAP) in the diagnosis of central nervous system germinoma. ( 15725806 )
2005
13
Patterns of failure after induction chemotherapy followed by consolidative radiation therapy for children with central nervous system germinoma. ( 14595717 )
2003
14
Induction chemotherapy followed by reduced-volume radiation therapy for newly diagnosed central nervous system germinoma. ( 9420074 )
1998
15
Radiation therapy for histologically confirmed primary central nervous system germinoma. ( 9276355 )
1997
16
Hormonal and metabolic abnormalities associated with central nervous system germinoma in children and adolescents and the effect of therapy: report of 10 patients. ( 6256407 )
1981
Sources

Variations for Central Nervous System Germinoma

About this section
Sources

Expression for Central Nervous System Germinoma

About this section
Search GEO for disease gene expression data for Central Nervous System Germinoma.
Sources

Pathways for Central Nervous System Germinoma

About this section

Pathways related to Central Nervous System Germinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.37 AVP POU5F1
2
G alpha (s) signalling events 67
11.12 AVP POMC
3
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 66
10.75 ALPP POU5F1
Sources

GO Terms for Central Nervous System Germinoma

About this section

Cellular components related to Central Nervous System Germinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 secretory granule GO:0030141 8.62 AVP POMC

Biological processes related to Central Nervous System Germinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 generation of precursor metabolites and energy GO:0006091 8.62 AVP POMC

Molecular functions related to Central Nervous System Germinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.96 AVP POMC
2 transcription regulatory region sequence-specific DNA binding GO:0000976 8.62 JMJD1C POU5F1
Sources

Sources for Central Nervous System Germinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....